Enabling gerotherapy for healthy aging
and age-related chronic disease
Aging is a biological program that is characterized by a gradual decline in physiological and mental fitness and increasing susceptibility to disease. The WHO has assigned „aging-associated decline in intrinsic capacity“ an international classification of disease (ICD)-11 code. This enables systematic and regulated development of preventive strategies for healthy aging as well as treatment for age-related chronic disease based on a molecular taxonomy of hallmarks of aging. If left untreated, these processes can converge in chronic inflammation, metabolic and cardiovascular disease, fibrotic and degenerative disorders, and cancer.
Novel gerotherapeutics comprising nutraceuticals, small molecule drugs, as well as other therapeutic modalities can modulate cellular processes and the signal transduction networks of aging to improve health span, reverse chronicity, and treat age-related disease.
Our epiQ.bio technology and screening platform utilizes select master regulators of aging programs to identify and functionally characterize next generation gerotherapeutics for healthy aging and treatment of age-related disease.
Our platform is validated using clinical and proprietary reference compounds with utility for restoring regenerative capacity and energy metabolism of cells and organs and the treatment of metabolic, degenerative and fibrotic disorders.
Disruptive potential of epigenetic actuators of aging and age-related disease
Epigenetic master regulators are actuators that play essential roles in aging, senescence, and age-related disease.
They integrate metabolism, inflammatory signaling, senescence, regeneration and other essential processes to balance the regenerative capacity of cells and organs.
Epigenetic master regulators respond dynamically to risk factors, environment, and lifestyle via regulatory hubs of aging accelerators (gerogenes) and aging decelerators (gerosuppressors).
epiQ.bio’s portfolio of epigenetic master regulators of aging comprises a class of long non-coding RNA (lncRNA)-guided epigenetic actuators. Binding of the lncRNA to the actuator serves as an ON/OFF switch and at the same time recruits the epigenetic actuator to regulated genes involved in aging. These genes control lipid metabolism and inflammatory processes and are further involved in tissue degeneration and fibrotic disease including hepatocyte senescence, liver fibrosis, as well as age-related cardiac dysfunction.
epiQ.bio’s technology and screening platform enables identification and mechanistic characterization of molecules that specifically interfere with lncRNA:actuator interaction to identify a transformative new class of specific modulators of epigenetic regulators of aging.
This provides unique opportunities to identify and develop gerotherapeutics with unique bandwidth as part of a preventive and safeguarding strategy for healthy aging and simultaneously enable pharmacological treatment of age-related chronic disease.
Industry-scale technology and screening platform
Our epiQ.bio technology platform enables screening, validation, and mechanistic characterization of small molecule modulators of epigenetic actuators and other regulators of gene expression that are controlled by long non-coding RNAs (lncRNAs).
We quantitatively assess biological activity of lncRNA-guided epigenetic actuators and regulators of gene expression by measuring lncRNA:actuator interaction. This functional assessment can be performed with select molecules, tailored industry-specific molecule libraries, pharmaceutical industry-scale high throughput-screening (HTS) libraries, as well as plant-based products & extracts, and phytochemical products.
We can serve various industries from health & nutrition industry to biotech and pharmaceutical industry to satisfy their demand for high value molecules with validated mechanism of action as well as biological and biomedical impact.
Modulating the activity of epigenetic master regulators with gerotherapeutics
